Cover Image
Market Research Report

Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025

Published by MarketsandMarkets Product code 940127
Published Content info 177 Pages
Delivery time: 1-2 business days
Price
Back to Top
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) - Global Forecast to 2025
Published: May 29, 2020 Content info: 177 Pages
Description

"The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020-2025)."

The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies over conventional treatments and a growing prevalence of target indications. However, timeline issues, side-effects, and manufacturing complexities are expected to restrict market growth to a certain extent.

"Monoclonal antibodies are expected to witness high demand during the forecast period."

The adoption of immunotherapy in cancer has been rising in recent years due to the introduction of safe and efficient treatments. Monoclonal antibodies are immunoglobulins derived by cultivating immune cells in the lab to target specific antigens present on the surface of cancer cells. These antibodies, when used as a therapy, attach themselves to cancer/abnormal cells and mark them for destruction by the body's natural immune system. Monoclonal antibodies hold the largest share of the immunotherapy drugs market owing to their high specificity and few side-effects.

"Cancer is one of the key application areas for immunotherapies."

On the basis of the therapeutic area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Cancer accounted for the largest share of the immunotherapy drugs market in 2019. This is mainly due to the large number of approvals, rising prevalence of cancer, and growing research activity in this area, among other factors.

"By end user, hospitals accounted for the largest share of the immunotherapy drugs market in 2019."

On the basis of the end user, the global immunotherapy drugs market is segmented into hospitals, clinics, and other end users. Hospitals accounted for the largest share of the immunotherapy drugs market in 2019, mainly due to their high spending on immunotherapies and the availability of the necessary infrastructure and facilities to provide advanced treatments.

"The market in North America is projected to hold the largest share of the global immunotherapy drugs market."

North America is projected to dominate the market during the forecast period. This can be attributed to factors such as the rising prevalence of cancer and increasing initiatives by industry players. On the other hand, the Asia Pacific region is expected to grow at the highest CAGR of 11.9% during the forecast period due to factors such as aggressive investments by key market players and the increase in government spending on healthcare.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type (Supply-side): Tier 1: 29%, Tier 2: 37%, and Tier 3: 34%
  • By Category (Demand-side): Pharmaceutical & Biotechnology Companies: 55%, Hospitals and Reference Laboratories: 35%, and Academic & Research Institutes: 10%
  • By Designation: C-level: 35%, Director level: 25%, and Managers: 40%
  • By Region: North America: 35%, Europe: 32%, Asia: 22%, and the RoW: 11%

F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), and Merck & Co (US) are the key players operating in the immunotherapy drugs market. Others include Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany).

Research Coverage:

The report analyzes the immunotherapy drugs market and aims at estimating the market size and future growth potential of this market based on various segments such as product, type, application, end user, and region. The report also includes competitive analyses of the key players in this market, along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the immunotherapy drugs market. The report analyzes the market based on type, therapeutic area, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the immunotherapy drugs market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of immunotherapy drugs solutions across regions
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the immunotherapy drugs market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the immunotherapy drugs market
Table of Contents
Product Code: PH 3926

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET SCOPE
    • 1.2.1 MARKETS COVERED
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Breakdown of primary sources
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW
  • 4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE (2019)
  • 4.3 GEOGRAPHIC SNAPSHOT OF THE IMMUNOTHERAPY DRUGS MARKET
  • 4.4 PIPELINE OF PHASE 2/3 IMMUNOTHERAPY DRUGS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing adoption of immunotherapy drugs over conventional treatment regimens
      • 5.2.1.2 Rising prevalence of cancer and autoimmune & infectious diseases
      • 5.2.1.3 Increasing demand for monoclonal antibodies and biosimilars
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Timeline issues, side-effects, and manufacturing complexities
      • 5.2.2.2 High attrition rate in the product development cycle
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased demand for personalized medicines
      • 5.2.3.2 High scope for growth in emerging economies
      • 5.2.3.3 Development of affordable nanoparticles for deploying immunotherapies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 High cost of immunotherapy treatment, regional disparities, and lack of insurance coverage
      • 5.2.4.2 Side-effects and low efficacy of immunotherapy drugs
      • 5.2.4.3 Lack of awareness
      • 5.2.4.4 Delays in diagnosis and treatment
    • 5.2.5 IMPACT OF THE COVID-19 PANDEMIC ON THE IMMUNOTHERAPY DRUGS MARKET

6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 MONOCLONAL ANTIBODIES
    • 6.2.1 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019
  • 6.3 CHECKPOINT INHIBITORS
    • 6.3.1 CHECKPOINT INHIBITORS MARKET TO GROW OWING TO THEIR WIDE APPLICABILITY IN NUMEROUS CANCER TREATMENTS
  • 6.4 INTERFERONS & INTERLEUKINS
    • 6.4.1 INTERFERONS & INTERLEUKINS USE THE PATIENT'S IMMUNE SYSTEM, WHICH PROVIDES SIGNIFICANT BENEFITS
  • 6.5 OTHER IMMUNOTHERAPIES

7 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA

  • 7.1 INTRODUCTION
  • 7.2 CANCER
    • 7.2.1 MALIGNANT CANCERS
      • 7.2.1.1 Malignant cancers held the largest share of the immunotherapy drugs market in 2019
    • 7.2.2 BENIGN CANCERS
      • 7.2.2.1 Availability of a range of drugs for benign cancer treatment supports market growth
  • 7.3 AUTOIMMUNE & INFLAMMATORY DISEASES
    • 7.3.1 STRONG DEMAND FOR IMMUNOTHERAPIES BOLSTERS MARKET GROWTH IN THIS SEGMENT
  • 7.4 INFECTIOUS DISEASES
    • 7.4.1 INCREASING PREVALENCE AND RISE IN R&D SUPPORT MARKET GROWTH
  • 7.5 OTHER THERAPEUTIC AREAS

8 IMMUNOTHERAPY DRUGS MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    • 8.2.1 HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY DRUGS MARKET
  • 8.3 CLINICS
    • 8.3.1 CLINICS PROVIDE FOCUSED, PRIMARY-LEVEL CARE FOR PATIENTS AND CANNOT PROVIDE ADVANCED TREATMENTS
  • 8.4 OTHER END USERS

9 IMMUNOTHERAPY DRUGS MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
      • 9.2.1.1 US holds the largest share of the North American market
    • 9.2.2 CANADA
      • 9.2.2.1 Increasing prevalence of cancer and the growing availability of approved immunotherapy drugs to drive market growth
  • 9.3 EUROPE
    • 9.3.1 UK
      • 9.3.1.1 The UK accounts for the largest share of the European market
    • 9.3.2 GERMANY
      • 9.3.2.1 New law for biosimilars in Germany to drive market growth
    • 9.3.3 FRANCE
      • 9.3.3.1 Initiatives by leading pharma players to drive the French market for immunotherapy drugs
    • 9.3.4 ITALY
      • 9.3.4.1 Availability of reimbursement drives the market in Italy
    • 9.3.5 SPAIN
      • 9.3.5.1 Increasing incidences of cancer to drive market growth during the forecast period
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 CHINA
      • 9.4.1.1 Rising prevalence of cancer and other infectious diseases to boost the adoption of immunotherapy in China
    • 9.4.2 JAPAN
      • 9.4.2.1 Universal health coverage boosts the market for immunotherapy drugs in Japan
    • 9.4.3 INDIA
      • 9.4.3.1 High number of cancer specialty care hospitals to support market growth
    • 9.4.4 AUSTRALIA
      • 9.4.4.1 Government initiatives to pave the way for the development of the Australian immunotherapy drugs market
    • 9.4.5 REST OF ASIA PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST & AFRICA
      • 9.5.1.1 Infrastructural growth and favorable socioeconomic trends will support market growth in the MEA
    • 9.5.2 BRAZIL
      • 9.5.2.1 Government support and player interest in Brazil will drive the market
    • 9.5.3 REST OF LATIN AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET EVALUATION FRAMEWORK
  • 10.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS
  • 10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019)
    • 10.4.1 STARS
    • 10.4.2 EMERGING LEADERS
    • 10.4.3 PERVASIVE COMPANIES
    • 10.4.4 EMERGING COMPANIES
  • 10.5 COMPETITIVE SCENARIO
    • 10.5.1 KEY PARTNERSHIPS AND COLLABORATIONS
    • 10.5.2 KEY PRODUCT LAUNCHES
    • 10.5.3 KEY ACQUISITIONS
    • 10.5.4 KEY EXPANSIONS

11 COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, MnM View)*

  • 11.1 F. HOFFMANN-LA ROCHE
  • 11.2 PFIZER
  • 11.3 MERCK & CO
  • 11.4 NOVARTIS INTERNATIONAL AG
  • 11.5 JOHNSON & JOHNSON
  • 11.6 SANOFI
  • 11.7 GLAXOSMITHKLINE
  • 11.8 ABBVIE
  • 11.9 AMGEN
  • 11.10 BOEHRINGER INGELHEIM
  • 11.11 ASTRAZENECA
  • 11.12 ELI LILLY AND COMPANY
  • 11.13 IMMATICS BIOTECHNOLOGIES GMBH
  • 11.14 GENMAB
  • 11.15 BIONTECH SE
  • 11.16 GILEAD SCIENCES
  • 11.17 NBE THERAPEUTICS
  • 11.18 TEVA PHARMACEUTICALS
  • 11.19 BAYER AG
  • 11.20 BRISTOL-MYERS SQUIBB
  • 11.21 INCYTE CORPORATION

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 RELATED REPORTS
  • 12.4 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
  • TABLE 2 GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005-2018
  • TABLE 3 COST OF KEYTRUDA, BY REGION (2018)
  • TABLE 4 CHECKPOINT INHIBITORS COVERED BY THE AUSTRALIAN PBS, AS OF JUNE 2019
  • TABLE 5 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 6 THERAPEUTIC AREAS IN WHICH MONOCLONAL ANTIBODY THERAPIES ARE APPROVED
  • TABLE 7 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 8 CHECKPOINT INHIBITORS MARKET, BY REGION, 2018-2025(USD BILLION)
  • TABLE 9 INTERFERONS & INTERLEUKINS MARKET, BY REGION, 2014-2021 (USD BILLION)
  • TABLE 10 OTHER IMMUNOTHERAPIES MARKET, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 11 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 12 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 13 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 14 IMMUNOTHERAPY DRUGS MARKET FOR MALIGNANT CANCER, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 15 IMMUNOTHERAPY DRUGS MARKET FOR BENIGN CANCER, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 16 IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 17 IMMUNOTHERAPY DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 18 IMMUNOTHERAPY DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 19 IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 20 IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 21 IMMUNOTHERAPY DRUGS MARKET FOR CLINICS, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 22 IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION, 2018-2025 (USD BILLION)
  • TABLE 23 IMMUNOTHERAPY DRUGS MARKET , BY REGION, 2018-2025 (USD BILLION)
  • TABLE 24 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • TABLE 25 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 26 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 27 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 28 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 29 NEW CANCER CASES AND DEATHS IN THE US, BY TYPE, 2020
  • TABLE 30 US: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 31 US: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 32 US: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 33 US: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 34 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 35 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 36 CANADA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 37 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 38 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • TABLE 39 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 40 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 41 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 42 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 43 UK: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 44 UK: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 45 UK: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 46 UK: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 47 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 48 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 49 GERMANY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 50 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 51 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 52 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 53 FRANCE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 54 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 55 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 56 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 57 ITALY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 58 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 59 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 60 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 61 SPAIN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 62 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 63 ROE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 64 ROE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 65 ROE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 66 ROE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 67 APAC: INCREASE IN HEALTH EXPENDITURE, BY COUNTRY (USD PER CAPITA)
  • TABLE 68 APAC: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • TABLE 69 APAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 70 APAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 71 APAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 72 APAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 73 CANCER CASES IN CHINA, 2018
  • TABLE 74 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 75 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 76 CHINA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 77 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 78 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 79 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 80 JAPAN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 81 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 82 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 83 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 84 INDIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 85 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 86 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 87 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 88 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 89 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 90 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 91 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 92 ROAPAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 93 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 94 ROW: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018-2025 (USD BILLION)
  • TABLE 95 ROW: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 96 ROW: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 97 ROW: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 98 ROW: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 99 MEA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 100 MEA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 101 MEA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 102 MEA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 103 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 104 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 105 BRAZIL: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 106 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 107 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 108 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD BILLION)
  • TABLE 109 ROLATAM: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018-2025 (USD BILLION)
  • TABLE 110 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)
  • TABLE 111 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2016-2019)
  • TABLE 112 PRODUCT LAUNCHES (2016-2019)
  • TABLE 113 ACQUISITIONS (2016-2019)
  • TABLE 114 EXPANSIONS (2016-2019)

LIST OF FIGURES

  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 5 ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE
  • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • FIGURE 7 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY TYPE (2020)
  • FIGURE 8 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY THERAPEUTIC AREA, 2020 VS. 2025 (USD BILLION)
  • FIGURE 9 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY END USER, 2020 VS. 2025 (USD BILLION)
  • FIGURE 10 NORTH AMERICA DOMINATES THE MARKET, BUT APAC TO REGISTER THE HIGHEST GROWTH RATE
  • FIGURE 11 INCREASING ADOPTION OF IMMUNOTHERAPY DRUGS TO DRIVE THE MARKET
  • FIGURE 12 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET IN 2019
  • FIGURE 13 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE IMMUNOTHERAPY DRUGS MARKET FROM 2020 TO 2025
  • FIGURE 15 IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2019
  • FIGURE 16 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIGURE 17 APAC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIGURE 18 MARKET EVALUATION FRAMEWORK: COLLABORATIVE EFFORT WAS A PROMINENT TARGET FOR MARKET COMPANIES
  • FIGURE 19 IMMUNOTHERAPY DRUGS MARKET IN 2019
  • FIGURE 20 COMPETITIVE LEADERSHIP MAPPING: IMMUNOTHERAPY DRUGS MARKET
  • FIGURE 21 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2019)
  • FIGURE 22 PFIZER: COMPANY SNAPSHOT (2019)
  • FIGURE 23 MERCK & CO: COMPANY SNAPSHOT (2019)
  • FIGURE 24 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2019)
  • FIGURE 25 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
  • FIGURE 26 SANOFI: COMPANY SNAPSHOT (2019)
  • FIGURE 27 GLAXOSMITHKLINE: COMPANY SNAPSHOT (2019)
  • FIGURE 28 ABBVIE: COMPANY SNAPSHOT (2019)
  • FIGURE 29 AMGEN: COMPANY SNAPSHOT (2019)
  • FIGURE 30 ASTRAZENECA: COMPANY SNAPSHOT (2019)
  • FIGURE 31 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)
  • FIGURE 32 GENMAB: COMPANY SNAPSHOT (2019)
  • FIGURE 33 BIONTECH SE: COMPANY SNAPSHOT (2019)
  • FIGURE 34 GILEAD SCIENCES: COMPANY SNAPSHOT (2019)
Back to Top